Frontier Capital Management Co. LLC Invests $2.65 Million in Evolus, Inc. (NASDAQ:EOLS)

Frontier Capital Management Co. LLC bought a new stake in Evolus, Inc. (NASDAQ:EOLS) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 239,811 shares of the company’s stock, valued at approximately $2,648,000. Frontier Capital Management Co. LLC owned 0.38% of Evolus as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in EOLS. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Evolus by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock valued at $148,000 after acquiring an additional 1,291 shares during the period. Rhumbline Advisers grew its position in Evolus by 2.2% during the 4th quarter. Rhumbline Advisers now owns 80,149 shares of the company’s stock worth $885,000 after purchasing an additional 1,762 shares during the last quarter. Tradition Wealth Management LLC increased its stake in Evolus by 18.2% in the fourth quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company’s stock valued at $144,000 after purchasing an additional 2,000 shares during the period. MetLife Investment Management LLC increased its stake in Evolus by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 34,272 shares of the company’s stock valued at $378,000 after purchasing an additional 2,044 shares during the period. Finally, Teacher Retirement System of Texas raised its holdings in shares of Evolus by 19.5% in the fourth quarter. Teacher Retirement System of Texas now owns 14,084 shares of the company’s stock valued at $155,000 after buying an additional 2,302 shares during the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on EOLS shares. Barclays upped their price objective on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. BTIG Research initiated coverage on Evolus in a report on Thursday, April 17th. They set a “buy” rating and a $21.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Evolus in a research report on Thursday. Finally, HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of Evolus in a research report on Thursday, April 10th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Evolus presently has a consensus rating of “Buy” and an average target price of $23.75.

Insider Activity

In other Evolus news, Director Karah Herdman Parschauer sold 12,888 shares of the business’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total transaction of $167,415.12. Following the sale, the director now directly owns 32,183 shares in the company, valued at approximately $418,057.17. The trade was a 28.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the firm’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $60,147.36. Following the completion of the transaction, the chief marketing officer now owns 95,671 shares of the company’s stock, valued at approximately $1,268,597.46. This represents a 4.53 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 60,575 shares of company stock worth $794,369 in the last 90 days. 5.90% of the stock is currently owned by corporate insiders.

Evolus Trading Down 2.9 %

Shares of EOLS stock opened at $9.80 on Friday. Evolus, Inc. has a 1-year low of $8.67 and a 1-year high of $17.82. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The business’s fifty day moving average price is $11.66 and its 200 day moving average price is $12.58. The firm has a market capitalization of $631.82 million, a PE ratio of -10.77 and a beta of 1.11.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.